#1 Clinical Trials Search in Europe

Betula Verrucosa Pollen

This article explores recent clinical trials investigating the use of Betula Verrucosa Pollen (birch pollen) in the treatment of allergic rhinitis and rhinoconjunctivitis. These studies aim to assess the effectiveness and safety of various immunotherapy approaches using birch pollen extracts to alleviate symptoms in patients with birch pollen allergies. The trials focus on different formulations and administration methods, including subcutaneous injections and skin prick tests, to evaluate their potential in managing allergic reactions.

Table of Contents

What is Betula Verrucosa Pollen?

Betula Verrucosa Pollen, also known as Betula Pendula Pollen, is a substance derived from the pollen of birch trees[1]. Birch trees are common in many parts of the world, particularly in temperate regions. The pollen from these trees is a frequent cause of allergies, especially during the spring season when trees release their pollen into the air.

Medical Uses

While birch pollen is often associated with causing allergies, it is also used in medical treatments, particularly in the field of allergy therapy. The primary medical uses of Betula Verrucosa Pollen include:

  • Allergy Diagnosis: It is used in skin prick tests to diagnose birch pollen allergies[1].
  • Immunotherapy: Betula Verrucosa Pollen is used in the treatment of birch pollen-induced allergic conditions, such as allergic rhinitis (hay fever) and allergic rhinoconjunctivitis (affecting both nose and eyes)[2].

Administration

Betula Verrucosa Pollen is administered in different ways depending on its use:

  • Skin Prick Test: For diagnostic purposes, it is applied as a solution for skin-prick test[1].
  • Subcutaneous Immunotherapy (SCIT): For treatment purposes, it may be administered via subcutaneous injection[2].

Clinical Trials

Betula Verrucosa Pollen is currently being studied in clinical trials to further understand its effectiveness in treating allergies. Some ongoing studies include:

  • A trial investigating mannan-conjugated birch pollen allergoids for treating birch pollen-induced allergic rhinitis or rhinoconjunctivitis in adolescents and adults[2].
  • Studies examining its use in combination with other tree pollens for allergy treatment[1].

Potential Benefits

The potential benefits of Betula Verrucosa Pollen in allergy treatment include:

  • Reduction in allergy symptoms during birch pollen season
  • Decreased need for allergy medications
  • Improved quality of life for individuals with birch pollen allergies
  • Potential long-term modification of the allergic response

Side Effects and Precautions

While Betula Verrucosa Pollen is used to treat allergies, it can also cause allergic reactions, especially in sensitive individuals. Potential side effects may include:

  • Local reactions at the injection site (for SCIT)
  • Itching, redness, or swelling
  • In rare cases, more severe allergic reactions

It’s important to note that Betula Verrucosa Pollen treatments should only be administered under the supervision of a healthcare professional, typically an allergist. Patients with certain conditions, such as severe asthma or other serious health issues, may not be suitable candidates for this treatment[2].

Conclusion

Betula Verrucosa Pollen, while a common cause of allergies, also serves as a valuable tool in allergy diagnosis and treatment. Through its use in skin prick tests and immunotherapy, it helps healthcare providers manage birch pollen allergies more effectively. Ongoing clinical trials continue to explore its potential benefits and optimal use in allergy treatment. As with any medical treatment, it’s crucial to consult with a healthcare professional to determine if Betula Verrucosa Pollen-based treatments are appropriate for your specific situation.

Aspect Details
Study Focus Clinical trials on Betula Verrucosa Pollen (birch pollen) for allergic rhinitis and rhinoconjunctivitis
Treatment Types Subcutaneous immunotherapy, skin prick tests, mannan-conjugated birch pollen allergoids
Patient Population Adolescents and adults (12-65 years) with confirmed birch pollen allergies
Primary Outcomes Symptom reduction, medication use decrease, quality of life improvement
Secondary Outcomes Immunological changes, safety profile, effects on asthma (if applicable)
Study Designs Randomized, double-blind, placebo-controlled trials
Treatment Duration Typically one year, with assessment during birch pollen season
Key Measurements TCRS, TNSS, RMS, immunoglobulin levels, lung function tests

FAQ

  • What is Betula Verrucosa Pollen? Betula Verrucosa Pollen, also known as birch pollen, is a common allergen that causes seasonal allergic reactions in many people. It comes from the silver birch tree (Betula pendula) and is used in allergy treatments to help desensitize patients to birch pollen allergies.
  • What conditions are being studied in these clinical trials? The clinical trials are primarily focused on moderate to severe allergic rhinitis and rhinoconjunctivitis caused by birch pollen. Some studies also include patients with controlled asthma related to birch pollen allergies.
  • How is the effectiveness of the treatments measured? The effectiveness is measured using various methods, including symptom scores (like the Total Combined Rhinitis Score), medication use, quality of life questionnaires, and objective tests such as nasal provocation tests and immunoglobulin levels in the blood.
  • What are the main types of treatments being studied? The trials are studying different forms of immunotherapy, including subcutaneous injections of birch pollen extracts and skin prick tests. Some studies use modified allergens, such as mannan-conjugated birch pollen allergoids, to potentially improve treatment efficacy and safety.
  • Who can participate in these clinical trials? Participants typically include adolescents and adults (ages 12-65) with a confirmed birch pollen allergy, moderate to severe symptoms, and a history of allergic rhinitis or rhinoconjunctivitis for at least 1-2 years. Specific inclusion and exclusion criteria vary between studies.

Ongoing Clinical Trials on Betula Verrucosa Pollen

  • Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Bulgaria Germany Latvia Lithuania Poland

  • Study on the Effects of Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis

    Not recruiting

    3 1 1
    Investigated drugs:
    Germany

Glossary

  • Allergic Rhinitis: An allergic reaction affecting the nasal passages, causing symptoms such as sneezing, runny nose, and nasal congestion in response to allergens like pollen.
  • Rhinoconjunctivitis: A condition where both the nasal passages and eyes are affected by an allergic reaction, causing symptoms in both areas.
  • Immunotherapy: A treatment approach that aims to modify the immune system's response to allergens, typically by exposing the patient to gradually increasing amounts of the allergen over time.
  • Subcutaneous Immunotherapy (SCIT): A form of allergy treatment where allergen extracts are injected under the skin to help desensitize the immune system.
  • Allergoid: A modified form of an allergen that has been chemically altered to reduce its ability to cause allergic reactions while maintaining its ability to stimulate the immune system for therapeutic purposes.
  • Mannan-conjugated: A modification to allergens where they are attached to mannan, a type of complex sugar, to potentially enhance the effectiveness of immunotherapy.
  • Total Combined Rhinitis Score (TCRS): A measure used to assess the severity of allergic rhinitis symptoms and medication use in clinical trials.
  • Nasal Provocation Test (NPT): A diagnostic test where an allergen is applied directly to the nasal mucosa to evaluate the allergic response.
  • Forced Expiratory Volume 1 (FEV1): A lung function test that measures the amount of air a person can forcefully exhale in one second, often used to assess asthma severity.
  • Immunoglobulin E (IgE): An antibody produced by the immune system in response to allergens, playing a key role in allergic reactions.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-purethal-mites-for-adults-with-moderate-to-severe-allergic-rhinitis-or-rhinoconjunctivitis-due-to-house-dust-mite-allergy/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-mannan-conjugated-birch-pollen-allergoids-for-adolescents-and-adults-with-birch-pollen-induced-allergic-rhinitis-or-rhinoconjunctivitis/